Skip to content

Clinical Efficacy of PRP Therapy for the Face: A Self-Controlled Prospective Evaluation

Clinical Efficacy of PRP Therapy for the Face: A Self-Controlled Prospective Evaluation - Clinical Efficacy of PRP Therapy for the Face: A Self-Controlled Prospective Evaluation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000058413
Enrollment
10
Registered
2025-07-09
Start date
2025-04-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin tissue that has atrophied or changed due to aging, trauma, congenital etc.

Interventions

PRP is prepared using the patient&#39
s own blood as the source material. The prepared PRP is then administered to the patient&#39
s face. Injection is performed on both the right and left sides of the face as follows: Left side: PRP Right side: Normal saline The injections are performed using a mesotherapy device, with the t

Sponsors

Tokyo Chuo Beauty Clinic (TCB), BS Clinic, Umeda Osaka Ekimae Branch
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Individuals who meet all of the following criteria Have clear tissue deformity or atrophy due to congenital conditions, trauma, or aging Are expected to benefit from this treatment Wish to receive the treatment and have been deemed suitable for it by a physician Are able to attend outpatient visits adults Have provided written informed consent for this treatment

Exclusion criteria

Exclusion criteria: Have a clearly apparent infection in the area surrounding the injection site Have a predisposition to keloid formation Have an insufficient understanding of this treatment Lack the capacity to make an informed decision regarding this treatment Do not wish to receive this treatment or are unable to provide informed consent Are deemed inappropriate for the treatment by the physician, such as those with malignant tumors, infectious tumors, infectious diseases, or inflammatory diseases

Design outcomes

Primary

MeasureTime frame
Photographs and a patient satisfaction survey will be conducted at 1 month, 3 months, and 6 months after the start of treatment.

Secondary

MeasureTime frame
At 2 weeks and 1 month following the start of treatment, image analysis will be conducted with the neoVoir imaging system.

Countries

Japan

Contacts

Public ContactMasashi Umeda

Tokyo Chuo Beauty Clinic (TCB), BS Clinic, Umeda Osaka Ekimae Branch Tokyo Chuo Beauty Clinic (TCB), BS Clinic, Umeda Osaka Ekimae Branch

dr.umeda.masashi@tcb.or.jp06-6147-2581

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026